Biochemical and cellular pharmacology of cytosine arabinoside.
D000818:Animals; D016590:Aphidicolin; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism / Q000494:pharmacology; D001667:Binding, Competitive; D002460:Cell Line; D002470:Cell Survival; D002499:Centrifugation, Density Gradient; D003561:Cytarabine / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis / Q000378:metabolism; D004260:DNA Repair / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects; D004224:Diterpenes / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism; D006098:Granulocytes / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D007939:Leukemia L1210 / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism; D019384:Nucleic Acid Synthesis Inhibitors; D013698:Templates, Genetic; D014740:Vidarabine / Q000378:metabolism
D004224:Diterpenes; D019384:Nucleic Acid Synthesis Inhibitors; D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; D016590:Aphidicolin; D004247:DNA; D014740:Vidarabine